Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT02285920

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02285920
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02285920. Randomized; quadruple masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2017-06 (actual). Results posted on 2019-07-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
Acronym
SPin-D
Condition
End-Stage Renal Disease
Intervention (Drug)
Spironolactone
Lead sponsor
University of Pennsylvania (class: other)
Collaborator
Brigham and Women's Hospital (class: other)
Collaborator
George Washington University (class: other)
Collaborator
Vanderbilt University (class: other)
Collaborator
University of Washington (class: other)

Record details

Record id
cardio:ct-nct02285920
Content hash
355cf37b5bf5b4fd658e3b44ed41c895f36f395f9b4fcb3f25b52061087de2cb